Duke John D 4

What Happened

• John D. Duke, CEO of Harvard Bioscience, bought 5,000 shares in an open-market purchase on March 16, 2026 at $5.01 per share, for a total cash outlay of $25,050. This was a purchase (acquisition) rather than a sale.

Key Details

• Transaction date and price: 2026-03-16, 5,000 shares at $5.01 each.
• Transaction type/code: Open-market purchase (P).
• Cash value: $25,050.
• Shares owned after transaction: Not stated in the filing.
• Footnote highlights:
  • F1: The filing also references (a) this 5,000-share purchase, (b) an award of 50,000 time‑based RSUs vesting in three equal installments on August 8, 2026, 2027 and 2028, and (c) an award of 50,000 performance‑based RSUs that vest based on relative total shareholder return vs. the Russell 2000 measured from August 8, 2025 to the earlier of July 30, 2028 or a change of control. The reported target for the performance RSUs is 50,000; the maximum payout is 150% of that amount.
  • F2: A 10-for-1 reverse stock split on March 13, 2026 reduced previously reported RSU counts (e.g., 500,000 → 50,000) and the RSU figures in F1 reflect that adjustment.
• Filing timeliness: Form 4 filed on 2026-03-17 for the March 16 transaction — appears timely (Form 4s are normally due within two business days).

Context

• Purchases by executives can be taken by investors as a modest bullish signal because the insider is adding to holdings; the amount here ($25k) is relatively small.
• The RSU awards referenced are grants/awards, not immediate transferable shares; time‑based RSUs vest on set dates and performance RSUs only vest if TSR targets vs. the Russell 2000 are met (with potential upside to 150% of target).